Poly Medicure quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	525	403	+30.3%
EBITDA	125	106	+17.9%
EBITDA margin	23.8%	26.3%	−2.5 pts
Profit before tax	116	122	−4.8%
Net profit	85.3	93.1	−8.4%
EPS	₹8.49	₹9.19	−7.6%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	525	535	494	444	403	441	424	420	385	378	340	337	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	33.4	17.8	26.3	33.9	41.7	24.3	21.8	26.1	16.9	15.0	16.6	14.1
	559	552	520	478	445	465	446	446	402	393	356	351
	184	155	146	157	141	142	142	155	133	127	119	114
	2.7	1.4	1.6	1.2	0.9	2.5	3.3	1.2	0.9	1.4	1.1	2.8
	−46.8	21.7	8.0	−22.6	−14.7	2.9	1.2	−23.6	−5.2	3.2	−1.7	4.2
	127	126	115	88.8	75.1	78.9	77.9	78.1	70.8	69.4	60.4	58.3
	6.5	6.4	6.0	3.0	3.0	2.2	3.3	3.3	3.2	3.1	3.5	2.2
	36.3	38.2	28.8	24.9	23.3	21.0	21.5	20.9	19.6	16.2	16.2	16.0
	134	120	112	105	94.7	95.1	85.3	94.1	81.8	80.8	70.9	73.5
	443	469	417	357	323	345	335	329	304	301	269	271
	125	110	111	115	106	119	115	115	104	96.6	90.2	84.2
	88.8	72.2	82.4	89.8	82.9	98.4	93.0	94.5	84.3	80.4	74.0	68.2
Profit
	116	83.5	103	121	122	121	112	117	98.0	92.2	87.1	80.1
	0.0	0.0	−6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	116	83.5	95.9	121	122	121	112	117	98.0	92.2	87.1	80.1
	28.2	25.4	26.5	27.5	22.1	23.8	24.2	25.0	22.7	20.2	20.0	17.2
	3.9	−5.3	0.3	2.4	7.8	7.2	3.8	5.5	1.7	3.9	2.9	1.6
	32.0	20.2	26.8	29.9	29.9	31.0	28.0	30.5	24.4	24.1	22.8	18.8
	1.6	1.7	1.7	1.0	1.3	2.3	1.7	0.8	0.4	0.2	0.7	0.8
	85.3	65.0	70.8	91.8	93.1	91.8	85.2	87.5	74.0	68.4	65.0	62.2
	83.7	63.3	69.1	90.8	91.8	89.6	83.5	86.7	73.6	68.1	64.3	61.4
	−0.0	24.9	22.5	−0.2	−0.7	0.1	−0.2	0.1	−1.4	−0.1	0.2	−0.8
	85.2	89.9	93.3	91.6	92.4	92.0	85.0	87.5	72.7	68.3	65.3	61.4
	86.0	66.3	70.9	91.8	93.1	91.8	85.2	87.5	74.0	68.4	65.0	62.2
	−0.8	−1.3	−0.1	−0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per share
	₹8.49	₹6.54	₹7.00	₹9.06	₹9.19	₹8.92	₹8.48	₹9.01	₹7.71	₹7.12	₹6.78	₹6.48
	₹8.48	₹6.53	₹6.99	₹9.06	₹9.17	₹8.92	₹8.48	₹9.01	₹7.71	₹7.12	₹6.77	₹6.47
Other comprehensive income — detail
	−0.0	24.9	22.5	−0.2	−0.7	0.1	—	—	—	—	—	—
	−0.9	0.8	0.3	0.3	−1.2	−0.1	0.2	−0.5	−1.7	−0.0	0.1	−1.1
	−0.2	0.2	0.1	0.1	−0.3	−0.0	—	—	—	—	—	—
	—	—	—	—	—	—	0.1	−0.1	−0.4	−0.0	0.0	−0.3
	0.6	24.3	22.3	−0.5	0.2	0.2	−0.4	0.4	−0.1	−0.1	0.2	−0.0
	86.0	91.2	93.4	91.6	92.4	92.0	85.0	87.5	72.7	68.3	65.3	61.4
	−0.8	−1.3	−0.1	−0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per share — as-filed variants
	₹8.49	₹6.54	₹7.00	₹9.06	₹9.19	₹8.92	₹8.48	₹9.01	₹7.71	₹7.12	₹6.78	₹6.48
	₹8.48	₹6.53	₹6.99	₹9.06	₹9.17	₹8.92	₹8.48	₹9.01	₹7.71	₹7.12	₹6.77	₹6.47
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	386	356	338	308	276	293	278	287	257	247	222	216
	73.4%	66.7%	68.4%	69.4%	68.4%	66.6%	65.5%	68.4%	66.7%	65.3%	65.2%	64.1%
Adjusted (ex-exceptional items) — derived
	116	83.5	103	121	122	121	112	117	98.0	92.2	87.1	80.1
	0.0	0.0	−6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	85.3	65.0	75.7	91.8	93.1	91.8	85.2	87.5	74.0	68.4	65.0	62.2
	₹8.49	₹6.54	₹7.48	₹9.06	₹9.19	₹8.92	₹8.48	₹9.01	₹7.71	₹7.12	₹6.78	₹6.48

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

POLYMED₹1,446.00

Poly Medicure Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersPFIZER RAINBOW ONESOURCE KIMS JUBLPHARMA VIJAYA INDGN GRANULESMcap ₹14,657 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	337.3	339.6	378.1	384.8	420.0	424.2	440.8	403.2	443.9	493.7	534.5	525.4
Other Income	14.1	16.6	15.0	16.9	26.1	21.8	24.3	41.7	33.9	26.3	17.8	33.4
Total Income	351.4	356.2	393.0	401.7	446.1	446.0	465.1	444.9	477.8	519.9	552.3	558.8
Expenses
+ Cost of Materials Consumed	114.2	118.7	126.6	132.6	154.9	142.0	142.0	141.1	157.1	146.2	155.1	183.9
+ Purchases of Stock-in-Trade	2.8	1.1	1.4	0.9	1.2	3.3	2.5	0.9	1.2	1.6	1.4	2.7
+ Changes in Inventories	4.2	-1.7	3.2	-5.2	-23.6	1.2	2.9	-14.7	-22.6	8.0	21.7	-46.8
+ Employee Benefit Expense	58.3	60.4	69.4	70.8	78.1	77.9	78.9	75.1	88.8	115.2	126.1	126.9
+ Finance Costs	2.2	3.5	3.1	3.2	3.3	3.3	2.2	3.0	3.0	6.0	6.4	6.5
+ Depreciation & Amortisation	16.0	16.2	16.2	19.6	20.9	21.5	21.0	23.3	24.9	28.8	38.2	36.3
+ Other Expenses	73.5	70.9	80.8	81.8	94.1	85.3	95.1	94.7	104.7	111.5	119.8	133.6
Total Expenses	271.3	269.1	300.8	303.7	328.9	334.5	344.6	323.3	357.1	417.2	468.8	443.0
EBITDA	84.2	90.2	96.6	103.9	115.3	114.5	119.5	106.1	114.7	111.2	110.4	125.1
EBIT	68.2	74.0	80.4	84.3	94.5	93.0	98.4	82.9	89.8	82.4	72.2	88.8
Profit
PBT before Exceptional Items	80.1	87.1	92.2	98.0	117.2	111.5	120.6	121.6	120.7	102.7	83.5	115.8
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.8	0.0	0.0
Pretax Income	80.1	87.1	92.2	98.0	117.2	111.5	120.6	121.6	120.7	95.9	83.5	115.8
+ Current Tax	17.2	20.0	20.2	22.7	25.0	24.2	23.8	22.1	27.5	26.5	25.4	28.2
+ Deferred Tax	1.6	2.9	3.9	1.7	5.5	3.8	7.2	7.8	2.4	0.3	-5.3	3.9
Tax Expense	18.8	22.8	24.1	24.4	30.5	28.0	31.0	29.9	29.9	26.8	20.2	32.0
+ Share of Associates & JVs	0.8	0.7	0.2	0.4	0.8	1.7	2.3	1.3	1.0	1.7	1.7	1.6
Net Income	62.2	65.0	68.4	74.0	87.5	85.2	91.8	93.1	91.8	70.8	65.0	85.3
+ Net Income — Continuing Ops	61.4	64.3	68.1	73.6	86.7	83.5	89.6	91.8	90.8	69.1	63.3	83.7
+ Other Comprehensive Income	-0.8	0.2	-0.1	-1.4	0.1	-0.2	0.1	-0.7	-0.2	22.5	24.9	-0.0
Total Comprehensive Income	61.4	65.3	68.3	72.7	87.5	85.0	92.0	92.4	91.6	93.3	89.9	85.2
Net Income to Common	62.2	65.0	68.4	74.0	87.5	85.2	91.8	93.1	91.8	70.9	66.3	86.0
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.0	-0.1	-1.3	-0.8
Per Share
Basic EPS	6.48	6.78	7.12	7.71	9.01	8.48	8.92	9.19	9.06	7.00	6.54	8.49
Diluted EPS	6.47	6.77	7.12	7.71	9.01	8.48	8.92	9.17	9.06	6.99	6.53	8.48
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.1	-0.7	-0.2	22.5	24.9	-0.0
+ Items NOT to be Reclassified to P&L	-1.1	0.1	-0.0	-1.7	-0.5	0.2	-0.1	-1.2	0.3	0.3	0.8	-0.9
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.0	-0.3	0.1	0.1	0.2	-0.2
+ Tax on Items NOT to be Reclassified — alt tag	-0.3	0.0	-0.0	-0.4	-0.1	0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-0.0	0.2	-0.1	-0.1	0.4	-0.4	0.2	0.2	-0.5	22.3	24.3	0.6
Comprehensive Income — Owners of Parent	61.4	65.3	68.3	72.7	87.5	85.0	92.0	92.4	91.6	93.4	91.2	86.0
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.0	-0.1	-1.3	-0.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	6.48	6.78	7.12	7.71	9.01	8.48	8.92	9.19	9.06	7.00	6.54	8.49
Diluted EPS — Continuing Operations	6.47	6.77	7.12	7.71	9.01	8.48	8.92	9.17	9.06	6.99	6.53	8.48
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	216.1	221.6	246.9	256.5	287.5	277.7	293.4	276.0	308.2	337.9	356.3	385.6
Gross Margin %	64.06	65.24	65.30	66.67	68.45	65.46	66.56	68.45	69.44	68.45	66.67	73.40
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	80.1	87.1	92.2	98.0	117.2	111.5	120.6	121.6	120.7	102.7	83.5	115.8
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.8	0.0	0.0
Net Income Adj (tax-effected)	62.2	65.0	68.4	74.0	87.5	85.2	91.8	93.1	91.8	75.7	65.0	85.3
EPS Adj	6.48	6.78	7.12	7.71	9.01	8.48	8.92	9.19	9.06	7.48	6.54	8.49
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Paid Up Equity Capital	48.0	48.0	48.0	48.0	50.6	50.7	50.7	50.7	50.7	50.7	50.7	50.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Poly Medicure Q2 FY27 results date

Poly Medicure (NSE: POLYMED) will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, according to the board-meeting notice it filed on 29 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹86 crore, down 7.6% from ₹93.1 crore in Q1 FY26 and up 29.8% from ₹66.3 crore in Q4 FY26. Revenue from operations was ₹525 crore, up 30.3% year on year and down 1.7% from the previous quarter.

Board-meeting notice filed: 29 October 2026
Q2 FY26 results (a year earlier): 8 November 2025
Q1 FY27 results (the latest): 7 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 5 November 2026Thursday · notice filed 29 Oct
Q1 FY27 net profit: ₹86 Cr−7.6% vs Q1 FY26+29.8% vs Q4 FY26
Q1 FY27 revenue: ₹525 Cr+30.3% vs Q1 FY26−1.7% vs Q4 FY26
Q1 FY27 operating margin: 16.9%−3.6 pts vs Q1 FY26+3.4 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹91.8 CrRevenue ₹444 Cr
Q1 FY27 EPS (basic): ₹8.49

Questions

When will Poly Medicure announce its Q2 FY27 results?

On 5 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 29 October 2026). Last year it reported Q2 FY26 on 8 November 2025.

What were Poly Medicure's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹86 crore, down 7.6% from ₹93.1 crore in Q1 FY26 and up 29.8% from ₹66.3 crore in Q4 FY26. Revenue from operations was ₹525 crore, up 30.3% year on year and down 1.7% from the previous quarter.

What was Poly Medicure's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹322 crore in FY26 (April 2025–March 2026), down 4.8% from ₹339 crore in FY25. It was ₹258 crore in FY24 and ₹179 crore in FY23: up 79.7% over three years, 21.6% a year on average.

What will Poly Medicure's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹91.8 crore and revenue from operations ₹444 crore. The latest quarter, Q1 FY27, had a net profit of ₹86 crore and revenue of ₹525 crore.

How has Poly Medicure's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹91.8 crore in Q2 FY26, ₹70.9 crore in Q3 FY26, ₹66.3 crore in Q4 FY26 and ₹86 crore in Q1 FY27. That is ₹315 crore over the four quarters, down 11.9% from ₹358 crore in the four quarters before. Revenue from operations: ₹444 crore, ₹494 crore, ₹535 crore and ₹525 crore.

What was Poly Medicure's revenue in FY26?

Revenue from operations was ₹1,875 crore in FY26 (April 2025–March 2026), up 12.3% from ₹1,670 crore in FY25. It was ₹1,376 crore in FY24 and ₹1,115 crore in FY23: up 68.1% over three years, 18.9% a year on average.

Where do these Poly Medicure figures come from?

From Poly Medicure's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.